TSLP and asthma: Tezepelumab, a TSLP antagonist used for asthma and atopic dermatitis, has a mechanism of action that targets the top of the inflammatory cascade, and a recent clinical trial has started to evaluate its role in improving outcomes for EoE patients [128,129].